

# MEETING SUMMARY

## Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases



Konstantinos Papamichael,<sup>\*,a</sup> Adam S. Cheifetz,<sup>\*,a</sup> Gil Y. Melmed,<sup>‡</sup> Peter M. Irving,<sup>§</sup> Niels Vande Casteele,<sup>||</sup> Patricia L. Kozuch,<sup>¶</sup> Laura E. Raffals,<sup>#</sup> Leonard Baidoo,<sup>\*\*</sup> Brian Bressler,<sup>‡‡</sup> Shane M. Devlin,<sup>§§</sup> Jennifer Jones,<sup>|||</sup> Gilaad G. Kaplan,<sup>§§</sup> Miles P. Sparrow,<sup>¶¶</sup> Fernando S. Velayos,<sup>##</sup> Thomas Ullman,<sup>\*\*\*</sup> and Corey A. Siegel<sup>†††</sup>

<sup>\*</sup>Beth Israel Deaconess Medical Center, Boston, Massachusetts; <sup>‡</sup>Cedars-Sinai Medical Center, Los Angeles, California; <sup>§</sup>Guy's and St. Thomas' Hospitals, London, United Kingdom; <sup>||</sup>University of California San Diego, La Jolla, California; <sup>¶</sup>Thomas Jefferson University, Philadelphia, Pennsylvania; <sup>#</sup>Mayo Clinic, Rochester, Minnesota; <sup>\*\*</sup>Northwestern University Feinberg School of Medicine, Chicago, Illinois; <sup>‡‡</sup>University of British Columbia, Vancouver, Canada; <sup>§§</sup>University of Calgary, Calgary, Alberta, Canada; <sup>|||</sup>Dalhousie University, Halifax, Canada; <sup>¶¶</sup>Alfred Hospital, Melbourne, Australia; <sup>##</sup>University of California San Francisco, San Francisco, California; <sup>\*\*\*</sup>Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York; and <sup>†††</sup>Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

**BACKGROUND & AIMS:** Therapeutic drug monitoring (TDM) is widely available for biologic therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and provided expert opinion regarding the clinical utility of TDM for biologic therapies in IBD.

**METHODS:** We used a modified Delphi method to establish consensus. A comprehensive literature review was performed regarding the use of TDM of biologic therapy in IBD and presented to international IBD specialists. Subsequently, 28 statements on the application of TDM in clinical practice were rated on a scale of 1 to 10 (1 = strongly disagree and 10 = strongly agree) by each of the panellists. Statements were accepted if 80% or more of the participants agreed with a score  $\geq 7$ . The remaining statements were discussed and revised based on the available evidence followed by a second round of voting.

**RESULTS:** The panel agreed on 24 (86%) statements. For anti-tumor necrosis factor (anti-TNF) therapies, proactive TDM was found to be appropriate after induction and at least once during maintenance therapy, but this was not the case for the other biologics. Reactive TDM was appropriate for all agents both for primary non-response and secondary loss of response. The panellists also agreed on several statements regarding TDM and appropriate drug and anti-drug antibody (ADA) concentration thresholds for biologics in specific clinical scenarios.

**CONCLUSION:** Consensus was achieved towards the utility of TDM of biologics in IBD, particularly anti-TNF therapies. More data are needed especially on non-anti-TNF biologics to further define optimal drug concentration and ADA thresholds as these can vary depending on the therapeutic outcomes assessed.

**Keywords:** Consensus Statement; Crohn's Disease; Ulcerative Colitis; Immunogenicity; Anti-TNF; Vedolizumab; Ustekinumab.

<sup>a</sup>Authors share co-first authorship.

**Abbreviations used in this paper:** ADA, anti-drug antibodies; ATI, antibodies to infliximab; CD, Crohn's disease; ELISA, enzyme-linked immunosorbent assay; HMSA, homogeneous mobility shift assay; IBD, inflammatory bowel disease; PD, pharmacodynamics; PK, pharmacokinetic; PNR, primary non-response; RCT, randomized controlled trial; SLR, secondary loss of response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor; UC, ulcerative colitis.

Most current article

© 2019 by the AGA Institute. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1542-3565

<https://doi.org/10.1016/j.cgh.2019.03.037>

See editorial on page 1718.

Biologic therapies, including the anti-tumor necrosis factor (anti-TNF) agents (infliximab, adalimumab, certolizumab pegol, and golimumab), the adhesion molecule inhibitors (vedolizumab and natalizumab), and the p-40 interleukin 12/23 inhibitor ustekinumab, are effective treatments for patients with moderate to severe inflammatory bowel disease (IBD).<sup>1,2</sup> Nevertheless, up to one-third of patients with Crohn's disease (CD) and ulcerative colitis (UC) show primary non-response (PNR) to biologic therapies, and up to 50% of patients after an initial clinical response stop therapy for either secondary loss of response (SLR) or a serious adverse event.<sup>3,4</sup> Both PNR and SLR are due to either pharmacokinetic (PK) or pharmacodynamic (PD) problems. PK issues are associated with inadequate drug exposure, often because of the development of anti-drug antibodies (ADA), whereas PD issues are typically related to inflammatory process unrelated to the targeted immunoinflammatory pathway.<sup>5,6</sup>

Numerous studies have demonstrated a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes, whereas low or undetectable drug concentrations can lead to immunogenicity and treatment failure (Tables 1–3, Supplementary Table 1).<sup>7–95</sup> Therapeutic drug monitoring (TDM), defined as the assessment of drug concentrations and ADA, is an important tool for optimizing biologic therapy. Reactive TDM has rationalized the management of PNR and SLR and has proven more cost-effective when compared with empiric dose escalation.<sup>96–102</sup> Preliminary data suggest that proactive TDM, with drug titration to a target trough concentration, performed in patients with clinical response/remission can also improve the efficacy of anti-TNFs.<sup>38,39,103,104</sup> Moreover, proactive TDM may also improve the cost-effectiveness and safety of biologic therapy via the implementation of a de-escalation strategy in patients with supratherapeutic drug concentrations by reducing the dose, increasing the time interval, and/or stopping the immunomodulator in patients on combination therapy (optimized monotherapy).<sup>39,82,105–107</sup>

However, there are still some limitations when applying TDM into clinical practice, such as when to use TDM, proper interpretation and application of the results, and the identification of the optimal window/thresholds to target. These therapeutic windows or thresholds appear to vary on the basis of the outcome of interest and the IBD phenotype (Tables 1 and 2, Supplementary Table 1). Moreover, most of the data on implementation of TDM refer to anti-TNF therapies and the maintenance phase of treatment.

We aimed to reach a consensus on when and how to use TDM of biologic therapies during different phases of the treatment (ie, induction, post-induction, and maintenance therapy) and sought to identify clinically relevant drug concentrations and ADA thresholds to help physicians apply TDM in clinical practice.

## Methods

We applied a modified Delphi method to establish consensus similar to that described in the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program.<sup>108</sup> A comprehensive literature review was performed regarding the use of TDM of biologic therapies in IBD by using PubMed and Medline databases. We used the following search terms: “inflammatory bowel disease”; “Crohn's disease”; “ulcerative colitis”; “anti-drug antibodies”; “therapeutic drug monitoring” AND “infliximab” OR “adalimumab” OR “certolizumab pegol” OR “golimumab” OR “vedolizumab” OR “ustekinumab”. The literature was then presented to a panel of 13 international IBD specialists. Subsequently, on the basis of this review, 28 statements were formulated (K.P., A.S.C., C.A.S.) describing when and how to apply TDM in clinical practice. An Expert Consensus Development Meeting consisting of members of the BRIDGE group ([www.BRIDGEIBD.com](http://www.BRIDGEIBD.com)) and TDM specialists was held in New Orleans on December 9, 2017 to refine and vote anonymously on the statements. Each statement was rated on a scale of 1–10 (1 = strongly disagree, 10 = strongly agree). Statements were accepted if 80% or more of the participants agreed with a score  $\geq 7$ . If less than 80% of the panelists agreed with a score  $\geq 7$ , statements were discussed and revised on the basis of the available evidence, followed by a second round of voting. The word *appropriate* was used for each statement to suggest that application of TDM for treatment optimization in a particular clinical scenario is a good option. However, these are not recommendations applicable to every patient.

## Results

The panel reached consensus on 24 of 28 statements (86%) (Tables 4 and 5).

### *Scenarios When Therapeutic Drug Monitoring of Biologic Therapies Should Be Performed*

**Anti-tumor necrosis factor therapy.** On the basis of the literature review, consensus was reached on all 4 statements regarding anti-TNFs (Table 4).

1. It is appropriate to order drug/antibody concentration testing in responders at the end of induction for all anti-TNFs.
2. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on all anti-TNFs.
3. It is appropriate to order drug/antibody concentration testing of anti-TNFs at the end of induction in primary non-responders.
4. It is appropriate to order drug/antibody concentration testing for all anti-TNFs in patients with confirmed secondary loss of response.

**Table 1.** Serum Adalimumab Concentration Thresholds Associated With Therapeutic Outcomes in Inflammatory Bowel Disease

IBD type	Threshold ( $\mu\text{g/mL}$ )	Therapeutic outcome	TDM assay	Assay type	Reference
Induction (week 2)					
CD	>6.7	Clinical remission (w14)	ELISA	AHLC	23
Post-induction (week 4)					
CD	>5	Drug retention	HMSA	Prometheus	29
CD	>12	Normal CRP ( $\leq 5$ mg/L)	ELISA	LFA/ELISA (R-Biopharm AG)	31
UC	$\geq 7.5$	Mucosal healing (w10–14)	ELISA	Leuven assay	30
UC	>4.6	Clinical response (w12)	ELISA	Leuven assay	26
UC	>7	Clinical response (w52)	ELISA	Leuven assay	26
Maintenance					
CD	>5.9	Normal CRP ( $\leq 5$ mg/L)	ELISA	AHLC	15
CD	>5.9	Normal CRP ( $\leq 3$ mg/L)	ELISA	Sumitomo Bakelite Co Ltd	16
CD	>8.1	Mucosal healing	HMSA	Prometheus	18
CD	>5.6	Normal CRP ( $\leq 3$ mg/L)	ELISA	In-house	19
CD	>7.9	Mucosal healing	ELISA	In-house	19
CD	>10.3	Mucosal healing	ELISA	In-house	20
CD	>5 (w26)	Clinical remission (w52)	ELISA	Sanquin Diagnostics	21
CD	$\geq 12$	Endoscopic remission	HMSA	Prometheus	22
CD	$\geq 12.2$	Histologic remission	HMSA	Prometheus	22
CD	$\geq 3.7$ (w14)	CRP normalization (w14)	ELISA	AHLC	23
CD/UC	>6.6	Normal CRP ( $\leq 5$ mg/L)	ELISA	AHLC	13
CD/UC	$\geq 6.9$	No SLR	RIA	Biomonitor A/S	14
CD/UC	>7.1	Mucosal healing	ELISA	AHLC	13
CD/UC	>4.9	Mucosal healing	ELISA	Theradiag	9
CD/UC	>7.8	Histologic remission	HMSA	Prometheus	12
CD/UC	>7.5	Mucosal healing	HMSA	Prometheus	12
CD/UC	>12.2	Successful dose reduction	ELISA	Promonitor Grifols	11
CD/UC	>9	Clinical response	ELISA	Promonitor Grifols	11
CD/UC	>6.6	Normal CRP ( $\leq 5$ mg/L)	ELISA	Promonitor Grifols	11
CD/UC	>4.5	When SLR, better long-term outcome when change to a biological with a different mechanism of action compared with anti-TNF dosage increase or a switch within class	ELISA	AHLC	10
CD/UC	$\geq 3$	No active inflammation <sup>a</sup>	ELISA	AHLC	10
CD/UC	>4.9	When SLR, high risk of failure subsequently after changing to infliximab	ELISA	Theradiag	8
CD/UC	>7.3	Clinical remission	ELISA	New Zealand assay	7

AHLC, antihuman lambda chain; CD, Crohn's disease; CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; HMSA, homogeneous mobility shift assay; LFA, lateral flow-based assay; RIA, radioimmunoassay; SLR, secondary loss of response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor; UC, ulcerative colitis; w, week.

<sup>a</sup>Defined as increased CRP level and/or endoscopic/imaging documentation of inflammation.

Numerous studies have demonstrated a positive correlation between anti-TNF drug concentrations and favorable therapeutic outcomes (Tables 1 and 2, Supplementary Table 1). However, the great majority of TDM studies refer to infliximab. A large retrospective study showed that at least one TDM, either proactive and/or reactive of infliximab compared with lack of any TDM, was associated with less treatment failure.<sup>109</sup> Several studies have shown that reactive TDM can better identify the cause and consequently manage SLR to anti-TNF therapy, although the data for PNR are more scarce.<sup>4,5,8,10,110</sup> Reactive TDM to guide infliximab dose adjustment compared with clinical decision-making alone is associated with higher post-adjustment clinical response and endoscopic remission and fewer

hospitalizations.<sup>37</sup> Moreover, reactive TDM of infliximab was found more cost-effective than using clinical symptoms alone to guide therapeutic decisions.<sup>99,101,102,111</sup>

Proactive TDM of infliximab compared with empiric dose escalation and/or reactive TDM was found to be associated with increased drug retention.<sup>39</sup> The landmark randomized controlled trial (RCT), Trough Concentration Adapted Infliximab Treatment (TAXIT), despite failing to meet its primary endpoint, showed that proactive TDM of infliximab compared with clinically based dosing was associated with lower frequency of undetectable drug concentrations and lower risk of relapse.<sup>104</sup> In addition, in patients with CD and subtherapeutic drug concentrations, a one-time dose optimization improved clinical remission rates and C-reactive protein.<sup>104</sup> Furthermore, proactive

**Table 2.** Association of Serum Certolizumab Pegol, Golimumab, Vedolizumab, and Ustekinumab Concentration Thresholds With Therapeutic Outcomes in Inflammatory Bowel Disease

IBD type	Time point	Threshold ( $\mu\text{g/mL}$ )	Therapeutic outcome	TDM assay	Assay type	Reference
Certolizumab pegol						
CD	Post-induction (w6)	>31.8	Clinical response/remission (w6)	ELISA	UCB Pharma	94
CD	Post-induction (w6)	>31.9	Normal CRP ( $\leq 5$ mg/L) (w6)	ELISA	UCB Pharma	94
CD	Post-induction (w6)	>32.7	Normal FC ( $< 250$ mg/g) (w6)	ELISA	UCB Pharma	94
CD	Post-induction (w6)	>34.5	Normal FC ( $< 250$ mg/g) and CDAI ( $\leq 150$ ) (w6)	ELISA	UCB Pharma	94
CD	Post-induction (w6)	>36.1	Normal FC ( $< 250$ mg/g) and CDAI ( $\leq 150$ ) (w26)	ELISA	UCB Pharma	94
CD	Post-induction (w8)	>23.3	Endoscopic remission (w10)	ELISA	UCB Pharma	95
CD	Maintenance (w12)	>13.8	Normal FC ( $< 250$ mg/g) (w26)	ELISA	UCB Pharma	94
CD	Maintenance (w12)	>14.8	Normal FC ( $< 250$ mg/g) and CDAI ( $\leq 150$ ) (w26)	ELISA	UCB Pharma	94
Golimumab						
UC	Induction (w2)	>8.9	Clinical response (w6)	ECLIA	Janssen Biotech Inc	48
UC	Post-induction (w4)	>7.4	Clinical response (w6)	ECLIA	Janssen Biotech Inc	48
UC	Post-induction (w6)	>2.5	Clinical response (w6)	ECLIA	Janssen Biotech Inc	48
UC	Post-induction (w6)	>2.6	Partial clinical response (w14)	ELISA	In-house Leuven	93
UC	Maintenance (w28)	>0.9	Clinical remission (w30 and 54)	ECLIA	Janssen Biotech Inc	48
UC	Maintenance (w44)	>1.4	Clinical remission (w30 and 54)	ECLIA	Janssen Biotech Inc	48
Vedolizumab						
CD	Induction (w2)	>35.2	Biological remission (w6)	ELISA	Leuven assay	90
UC	Induction (w2)	>28.9	Clinical response (w14)	ELISA	Leuven assay	90
UC	Induction (w2)	>23.7	Mucosal healing (w14)	ELISA	Leuven assay	90
CD/UC	Induction (w2)	$\geq 24.5$	No drug optimization (within w24)	ELISA	Theradiag	92
UC	Induction (w6)	>20.8	Clinical response (w14)	ELISA	Leuven assay	90
CD/UC	Induction (w6)	$\geq 18.5$	No need for extended therapy	ELISA	Theradiag	92
CD/UC	Induction (w6)	>27.5	Sustained clinical response	ELISA	Theradiag	92
CD/UC	Induction (w6)	>18	Mucosal healing (within w54)	ELISA	Theradiag	91
UC	Post-induction (w14)	>12.6	Clinical response (w14)	ELISA	Leuven assay	90
UC	Post-induction (w14)	>17	Mucosal healing (w14)	ELISA	Leuven assay	90
CD	Maintenance (w22)	>13.6	Mucosal healing (w22)	ELISA	Leuven assay	90
CD	Maintenance (w22)	>12	Biological remission (w22)	ELISA	Leuven assay	90
Ustekinumab						
CD	Post-induction (w8)	>3.3	Clinical remission (w8)	ECLIA	Janssen Biotech Inc	49
CD	Maintenance	>4.5	Endoscopic response	HMSA	Prometheus	89
CD	Maintenance (w24) <sup>a</sup>	>0.8	Clinical remission (w24)	ECLIA	Janssen Biotech Inc	49
CD	Maintenance (w40) <sup>b</sup>	>1.4	Clinical remission (w44)	ECLIA	Janssen Biotech Inc	49

CD, Crohn's disease; CDAI, Crohn's disease activity index; CRP, C-reactive protein; ECLIA, electrochemiluminescence immunoassay; ELISA, enzyme-linked immunosorbent assay; FC, fecal calprotectin; HMSA, homogeneous mobility shift assay; TDM, therapeutic drug monitoring; UC, ulcerative colitis; w, week.

<sup>a</sup>Combined every 8w and every 12w.

<sup>b</sup>Every 8w only.

compared with reactive TDM of infliximab was associated with greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions.<sup>38</sup> Recently, proactive after reactive TDM of infliximab was found to be associated with greater drug persistence and fewer IBD-related hospitalizations than reactive TDM alone.<sup>103</sup> Proactive TDM can also efficiently guide immunomodulator withdrawal in patients on combination therapy. This concept of optimized monotherapy was introduced in a retrospective study showing that patients with infliximab concentrations  $\geq 5$   $\mu\text{g/mL}$  had similar drug persistence when treated with infliximab monotherapy or combination therapy with an immunomodulator<sup>5</sup> and is further supported by a recent post hoc analysis of the RCT Study of Biologic and Immunomodulator Naïve Patients in Crohn's

Disease (SONIC), which demonstrated that patients stratified by infliximab trough quartiles had comparable outcomes regardless of concomitant azathioprine.<sup>112</sup>

**Vedolizumab.** Consensus was reached on only 2 of 4 statements regarding vedolizumab (Table 4).

7. It is appropriate to order drug/antibody concentration testing for vedolizumab in non-responders at the end of induction.
8. It is appropriate to order drug/antibody concentration testing for vedolizumab in patients with confirmed secondary loss of response.

The current evidence supporting the role of TDM regarding vedolizumab derives only from exposure-response relationship studies showing that higher

**Table 3.** Association of Anti-Drug Antibodies With Therapeutic Outcomes in Inflammatory Bowel Disease

Drug	IBD type	ADA	Therapeutic outcome	TDM assay	Assay type	Reference
IFX	CD	≥282 ng/mL-eq	Lower success rate of treatment optimization	ELISA	Leuven drug-tolerant assay	75
IFX	CD	>8 µg/mL-eq	Shorter clinical response	ELISA	Prometheus	28
IFX	CD	Detectable	Lack of mucosal healing	ELISA	MP Biomedicals	17
IFX	CD	Detectable	Elevated CRP (>5 mg/L)	HMSA	Prometheus	56
IFX	CD	Detectable	Elevated CRP (>5 mg/L)	HMSA	Prometheus	60
IFX	CD	Detectable	Lack of fistula healing	HMSA	Prometheus	12
IFX	CD	Detectable	SLR	ELISA	Prometheus	88
IFX	CD	Detectable	SLR	RIA	Biomonitor A/S	87
IFX	UC	Detectable	Lack of endoscopic response	HMSA	Prometheus	33
IFX	UC	Detectable	Lack of mucosal healing	ELISA	Leuven drug-tolerant assay	67
IFX	CD/UC	≥8.8 U/mL	Drug discontinuation	HMSA	Prometheus	86
IFX	CD/UC	Detectable	PNR	ELISA	AHLC	73
IFX	CD/UC	Detectable	Drug discontinuation	HMSA	Prometheus	63
IFX	CD/UC	>9.1 U/mL	Failure of dose intensification after SLR	HMSA	Prometheus	63
IFX	CD/UC	>12 U/mL	Surgery	HMSA	Prometheus	85
IFX	CD/UC	Undetectable	Mucosal healing	ELISA	AHLC	13
IFX	CD/UC	Undetectable	Short-term clinical response	HMSA	Prometheus	27
IFX	CD/UC	Detectable	SLR	ELISA	AHLC	32
IFX	CD/UC	Detectable	SLR	ELISA	AHLC	84
IFX	CD/UC	>9 µg/mL-eq	When SLR, longer duration of response when anti-TNF agents are switched than when dosage is increased	ELISA	AHLC	10
IFX	CD/UC	≥3.3 U/mL	Lack of post-adjustment endoscopic remission	HMSA	Prometheus	37
IFX	CD/UC	Detectable	Treatment-related adverse events	ELISA	Promonitor Menarini/ ImmunDiagnostik	83
IFX	CD/UC	Detectable <sup>a</sup>	PNR (w14)	ELISA	AHLC	73
IFX	CD/UC	>4.3 µg/mL-eq <sup>b</sup>	PNR (w14)	ELISA	AHLC	73
IFX	CD/UC	>9.1 U/mL	IFX discontinuation	HMSA	Prometheus	82
IFX	CD/UC	>9.1 U/mL	Infusion reactions	HMSA	Prometheus	82
IFX	CD/UC	>200 ng/mL-eq	No response to treatment optimization	ELISA	Theradiag	81
ADM	CD	Detectable	PNR	ELISA	AHLC	23
ADM	CD	Detectable	Drug discontinuation	HMSA	Prometheus	29
ADM	CD	Detectable	Drug discontinuation	ELISA	In-house <sup>c</sup>	57
ADM	CD	>12 U/mL	Lack of clinical response	RIA	Biomonitor A/S	58
ADM	CD	Detectable	Active disease	ELISA	AHLC	15
ADM	CD	Detectable	Higher CRP and ESR	ELISA	Sumitomo Bakelite Co, Ltd	16
ADM	CD	Detectable <sup>d</sup>	No clinical remission (w52)	RIA	Sanquin	21
ADM	CD	Detectable (w12)	Higher needs for dose escalation less frequently sustained clinical benefit due to PNR or SLR	ELISA	R-Biopharm AG	31
ADM	CD/UC	Detectable	Drug discontinuation	RIA	Biomonitor A/S	80
ADM	CD/UC	>4 µg/mL-eq	When SLR, longer duration of response when anti-TNF agents are switched than when dosage is increased	ELISA	AHLC	10
ADM	CD/UC	Detectable	SLR	RIA	Biomonitor A/S	14

ADA, anti-drug antibody; ADM, adalimumab; AHLC, antihuman lambda chain antibody; CD, Crohn's disease; CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation rate; HMSA, homogeneous mobility shift assay; IFX, infliximab; PNR, primary non-response; RIA, radioimmunoassay; SLR, secondary loss of response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor; UC, ulcerative colitis; w, week.

<sup>a</sup>Either week 2 or 6.

<sup>b</sup>Week 2.

<sup>c</sup>Université François-Rabelais, Immuno-Pharmaco-Genetics of Therapeutic Antibodies, Tours, France.

<sup>d</sup>Week 26.

**Table 4.** Scenarios of Applying Therapeutic Drug Monitoring of Biological Therapy in Patients With Inflammatory Bowel Disease

Statement	Vote agreement, %
<b>Anti-TNFs</b>	
1. It is appropriate to order drug/antibody concentration testing in responders at the end of induction for all anti-TNFs.	92 (12/13)
2. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on all anti-TNFs.	100 (13/13)
3. It is appropriate to order drug/antibody concentration testing of anti-TNFs at the end of induction in primary non-responders.	100 (13/13)
4. It is appropriate to order drug/antibody concentration testing for all anti-TNFs in patients with confirmed secondary loss of response.	100 (13/13)
<b>Vedolizumab</b>	
5. It is appropriate to order drug/antibody concentration testing for vedolizumab in responders at the end of induction.	15 (2/13) <sup>a</sup>
6. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on vedolizumab.	46 (6/13) <sup>a</sup>
7. It is appropriate to order drug/antibody concentration testing for vedolizumab in non-responders at the end of induction.	92 (12/13)
8. It is appropriate to order drug/antibody concentration testing for vedolizumab in patients with confirmed secondary loss of response.	83 (10/12) <sup>a</sup>
<b>Ustekinumab</b>	
9. It is appropriate to order drug/antibody concentration testing for ustekinumab in responders at the end of induction.	39 (5/13) <sup>a</sup>
10. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on ustekinumab.	31 (4/13) <sup>a</sup>
11. It is appropriate to order drug/antibody concentration testing for ustekinumab in non-responders at the end of induction (at 8 weeks).	92 (12/13)
12. It is appropriate to order drug/antibody concentration testing for ustekinumab in patients with confirmed secondary loss of response.	83 (10/12) <sup>a</sup>

TNF, tumor necrosis factor.

<sup>a</sup>After a second round of voting.

vedolizumab concentrations are associated with better therapeutic outcomes (Table 2).<sup>90-92,113</sup> In particular, a large single-center retrospective cohort study of 179 patients (66 with UC and 113 with CD) showed that higher vedolizumab trough concentrations at weeks 2 and 6 were associated with a higher probability of attaining endoscopic healing, clinical response and biologic response, or remission assessed at week 14 for UC and week 22 for CD.<sup>90</sup> A multicenter prospective observational study identified a vedolizumab trough concentration cutoff of 18  $\mu\text{g/mL}$  at week 6 as the only independent variable associated with mucosal healing within the first year of treatment.<sup>91</sup> Currently, there are no studies comparing either proactive or reactive TDM with symptom-based vedolizumab optimization.

**Ustekinumab.** Consensus was reached on only 2 of 4 statements regarding ustekinumab (Table 4).

11. It is appropriate to order drug/antibody concentration testing for ustekinumab in non-responders at the end of induction (at 8 weeks).
12. It is appropriate to order drug/antibody concentration testing for ustekinumab in patients with confirmed secondary loss of response.

The current evidence supporting the role of TDM regarding ustekinumab is based on 2 exposure-response relationship studies showing that higher ustekinumab concentrations correlate to better therapeutic outcomes (Table 2).<sup>49,89</sup> At this time, there are still no studies comparing either proactive or reactive TDM with empiric ustekinumab optimization.

### Assays, Drug Concentrations, and Anti-Drug Antibodies

**General.** Consensus was reached on all 4 statements regarding the use of biologic drug concentrations and anti-drug antibodies (Table 5).

13. There is no difference in indication for ordering drug/antibody concentrations or interpretation of results for biosimilars or originator drug.

Current data suggest that infliximab enzyme-linked immunosorbent assays (ELISAs) for evaluating either drug concentrations or antibodies to infliximab (ATI) are suitable for monitoring the infliximab biosimilars SB2 and CT-P13.<sup>114-117</sup>

14. The threshold drug concentration may vary depending on disease phenotype and desired therapeutic outcome.

Numerous studies have shown an association between higher induction or maintenance biologic drug concentrations and favorable therapeutic outcomes in IBD (Tables 1 and 2, Supplementary Table 1). Current exposure-response relationship studies suggest that biologic drug concentration thresholds and ranges appear to differ depending on treatment goals and/or disease phenotypes. In general, higher drug concentrations tend to be associated with more stringent outcomes, and higher drug concentrations appear to be needed for phenotypes with a higher inflammatory burden, such as fistulizing CD (Tables 1 and 2, Supplementary Table 1, Figure 1).

15. In the presence of adequate trough drug concentrations, anti-drug antibodies are unlikely to be clinically relevant.

A study from Steenholdt et al<sup>118</sup> showed that most ATI detected via the drug-tolerant homogeneous mobility-shift assay (HMSA) lack neutralizing potential when tested via a functional cell-based reporter-gene

**Table 5.** Biological Drug Concentrations and Anti-Drug Antibodies When Applying Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Statement	Vote agreement, %
<b>General</b>	
13. There is no difference in indication for ordering drug/antibody concentrations or interpretation of results for biosimilars or the originator drug.	100 (13/13)
14. The threshold drug concentration may vary depending on disease phenotype and desired therapeutic outcome.	100 (13/13)
15. In the presence of adequate trough drug concentrations, anti-drug antibodies are unlikely to be clinically relevant.	100 (12/12)
16. Other than for anti-infliximab antibodies, there are not enough data to recommend a threshold for high anti-drug antibody titers for the biologic drugs.	100 (12/12)
<b>Infliximab</b>	
17. The current evidence suggests that the variability of infliximab concentrations between the different assays is unlikely to be clinically significant.	100 (13/13) <sup>a</sup>
18. There is insufficient evidence that inter-assay drug concentration results are comparable for biologic drugs other than for infliximab.	100 (13/13)
19. The minimal trough concentration for infliximab post-induction at week 14 should be greater than 3 $\mu\text{g/mL}$ , and concentrations greater than 7 $\mu\text{g/mL}$ are associated with an increased likelihood of mucosal healing.	100 (13/13)
20. During maintenance the minimal trough concentration for infliximab for patients in remission should be greater than 3 $\mu\text{g/mL}$ . For patients with active disease, infliximab should generally not be abandoned unless drug concentrations are greater than 10 $\mu\text{g/mL}$ .	92 (12/13)
21. In the absence of detectable infliximab, high titer anti-infliximab antibodies require a change of therapy. Low level antibodies can sometimes be overcome. For the ANSER assay, a high titer anti-infliximab antibody at trough is defined as 10 U/mL, for RIDAscreen the cutoff is 200 ng/mL, and for InformTx/Lisa Tracker the cutoff is 200 ng/mL. For other assays, there are insufficient data to define an adequate cutoff for a high titer anti-infliximab antibody.	100 (13/13)
<b>Adalimumab</b>	
22. The minimum drug concentration at week 4 for adalimumab should at least be 5 $\mu\text{g/mL}$ . Drug concentrations greater than 7 $\mu\text{g/mL}$ are associated with an increased likelihood of mucosal healing.	83 (10/12) <sup>a</sup>
23. During maintenance the minimum trough concentration for adalimumab for patients in remission should be greater than 5 $\mu\text{g/mL}$ . For patients with active disease, adalimumab should generally not be abandoned unless drug concentrations are greater than 10 $\mu\text{g/mL}$ .	100 (12/12)
<b>Certolizumab pegol</b>	
24. The minimum concentrations for certolizumab pegol at week 6 should be greater than 32 $\mu\text{g/mL}$ .	100 (12/12)
25. During maintenance the minimum trough concentration for certolizumab pegol for patients in remission should be 15 $\mu\text{g/mL}$ .	92 (11/12)
<b>Golimumab</b>	
26. The minimum drug concentration at week 6 for golimumab should at least be 2.5 $\mu\text{g/mL}$ .	92 (11/12)
27. During maintenance the minimum trough concentration for golimumab for patients in remission should be greater than 1 $\mu\text{g/mL}$ .	92 (11/12)
<b>Vedolizumab/ustekinumab</b>	
28. Although there are emerging data that may show an association between drug concentrations and outcomes, they are not sufficient to guide specific induction and maintenance drug concentrations for vedolizumab and ustekinumab other than confirming that there is detectable drug.	100 (12/12)

<sup>a</sup>After a second round of voting.


assay, suggesting that they may not be clinically significant. A post hoc analysis of the TAXIT study, which investigated the additional benefit of a drug-tolerant assay, concluded that although it allowed closer follow-up of ATI concentrations and identification of true transient versus persistent antibodies, it offered no clinical benefit over a drug-sensitive assay.<sup>119</sup> Nevertheless, other studies have suggested that “double positive” patients (with positive ATI and drug on board) may be prone to SLR or lack of mucosal healing.<sup>60,67,120</sup>

16. Other than for ATI, there are not enough data to recommend a threshold for high anti-drug antibody titers for the biologic drugs.

Numerous studies have shown that ADA are associated with subtherapeutic drug trough concentrations, loss of response, and lack of recapture of response after dose escalation (Table 3).<sup>10,12–17,21,23,27–29,31–33,37,56–58,60,63,67,73,75,80–88</sup> However, the great majority of them and specifically the ones suggesting a threshold of high-titer ADA refer to ATI (Table 3).

**Infliximab.** Consensus was reached on all statements regarding infliximab concentrations and ATI (Table 5).

17. The current evidence suggests that the variability of infliximab concentrations between the different assays is unlikely to be clinically significant.



**Figure 1.** (A) Infliximab<sup>13,17,20,40–43,45,46,53,55,59–61,64,67</sup> and (B) adalimumab<sup>9,11–13,15,16,18–23,30,31</sup> concentration thresholds associated with biological (based on CRP), biochemical (based on FC), endoscopic, or histologic remission in inflammatory bowel disease. *Box whisker plots* show the median (*solid line within box*), interquartile range (*upper and lower box boundaries*), and lower and upper extreme (*whiskers*). ADM, adalimumab; CRP, C-reactive protein; FC, fecal calprotectin; IFX, infliximab.

18. There is insufficient evidence that inter-assay drug concentration results are comparable for biologic drugs other than for infliximab.

Current evidence suggests that although absolute drug concentrations can differ between different assays, including the commonly used ELISA, radioimmunoassay, HMSA, and the recently developed electrochemiluminescence immunoassay, they correlate well and generally lead to the same therapeutic decision.<sup>83,118,121–123</sup> However, these data refer mostly to infliximab, whereas there are only scarce data for adalimumab and none for non-anti-TNF agents.

19. The minimal trough concentration for infliximab post-induction at week 14 should be greater than 3 µg/mL, and concentrations greater than 7 µg/mL are associated with an increased likelihood of mucosal healing.
20. During maintenance the minimal trough concentration for infliximab for patients in remission should be greater than 3 µg/mL. For patients with active disease, infliximab should generally not be abandoned unless drug concentrations are greater than 10 µg/mL.

These drug concentration thresholds were mainly based on infliximab exposure-response relationship studies depicted in [Supplementary Table 1](#).

21. In the absence of detectable infliximab, high-titer ATI require a change of therapy. Low-level antibodies can sometimes be overcome. For the ANSER assay, a high-titer ATI at trough is defined as 10 U/mL, for RIDAscreen the cutoff is 200 ng/mL, and for InformTx/Lisa Tracker the cutoff is 200 ng/mL.

For other assays, there are insufficient data to define an adequate cutoff for a high-titer ATI.

Differences in assay methodology result in varying sensitivity to detect ADA and discrepancies when reporting ADA titers.<sup>122</sup> Therefore, clinically relevant ADA cutoffs are assay specific, referring mostly to ELISAs and the HMSA ([Table 3](#)). Vande Casteele et al<sup>63</sup> showed that ATI >9.1 U/mL (measured with the HMSA) at time of loss of response resulted in a likelihood ratio of 3.6 for an unsuccessful intervention, suggesting these ATI are sustained and probably very hard to overcome. Moreover, Yanai et al<sup>10</sup> showed ATI >9 µg/mL-eq can identify patients who do not respond to an increased drug dosage with 90% specificity. In addition, a small retrospective study of IBD patients in whom infliximab was optimized, either proactively or reactively, to overcome immunogenicity showed that an ATI titer <8.8 U/mL (measured with the HMSA) was associated with drug retention, suggesting that lower-titer ATI can often be overcome with dose intensification.<sup>86</sup> A post hoc analysis of the TAXIT trial showed that ATI >222 ng/mL-eq (measured with an in-house developed drug-tolerant ELISA) was not possible to be overcome after infliximab optimization.<sup>119</sup>

**Adalimumab.** Consensus was reached on all 2 statements regarding adalimumab concentrations and antibodies to adalimumab ([Table 5](#)).

22. The minimum drug concentration at week 4 for adalimumab should at least be 5 µg/mL. Drug concentrations greater than 7 µg/mL are associated with an increased likelihood of mucosal healing.
23. During maintenance the minimum trough concentration for adalimumab for patients in



remission should be greater than 5  $\mu\text{g/mL}$ . For patients with active disease adalimumab should generally not be abandoned unless drug concentrations are greater than 10  $\mu\text{g/mL}$ .

These drug concentration thresholds were based mainly on adalimumab exposure-response relationship studies depicted in [Table 1](#).

**Certolizumab pegol.** Consensus was reached on all 2 statements regarding certolizumab pegol concentrations and antibodies to certolizumab pegol ([Table 5](#)).

24. The minimum concentrations for certolizumab pegol at week 6 should be greater than 32  $\mu\text{g/mL}$ .
25. During maintenance the minimum trough concentration for certolizumab pegol for patients in remission should be 15  $\mu\text{g/mL}$ .

These drug concentration thresholds were based on certolizumab pegol exposure-response relationship studies depicted in [Table 2](#).

**Golimumab.** Consensus was reached on all 2 statements regarding golimumab concentrations and antibodies to golimumab ([Table 5](#)).

26. The minimum drug concentration at week 6 for golimumab should at least be 2.5  $\mu\text{g/mL}$ .
27. During maintenance the minimum trough concentration for golimumab for patients in remission should be greater than 1  $\mu\text{g/mL}$ .

These drug concentration thresholds were based on exposure-response relationship studies depicted in [Table 2](#).

**Vedolizumab and ustekinumab.** Consensus was reached on the statement regarding vedolizumab and ustekinumab concentrations and antibodies to vedolizumab or ustekinumab ([Table 5](#)).

28. Although there are emerging data that may show an association between drug concentrations and outcomes, they are not sufficient to guide specific induction and maintenance drug concentrations for vedolizumab and ustekinumab other than confirming that there is detectable drug.

At the time of the consensus meeting there were only limited data available from exposure-response relationship studies to suggest a clinically relevant vedolizumab or ustekinumab ([Table 2](#)) threshold or range associated with favorable therapeutic outcomes.

## Discussion

Unlike for rheumatoid arthritis and psoriasis, there are only a limited number of biologic agents approved for the treatment of IBD. In addition, current data demonstrate that patients who fail anti-TNF therapies do not respond as well to subsequent agents.<sup>124,125</sup> Thus,

optimizing the use of biologic therapies is of the utmost importance. TDM is one strategy to optimize biologics and maximize their effectiveness. Reactive TDM can better explain and manage SLR, and there is emerging evidence that proactive TDM further improves outcomes and is being used more frequently.<sup>126,127</sup>

In the recent American Gastroenterological Association guidelines, no recommendation was made regarding proactive TDM of anti-TNFs for patients who have quiescent disease because of a “knowledge gap”.<sup>96</sup> However, the IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group recommended that in patients in clinical remission after anti-TNF therapy induction, TDM should be considered to guide management, and also TDM should be considered periodically in patients in clinical remission if the results are likely to impact management.<sup>97</sup> Although well-designed large prospective studies are lacking, there are preliminary data mainly from retrospective studies that demonstrate that proactive TDM is associated with better therapeutic outcomes compared with empiric dose optimization and/or reactive TDM.<sup>38,39,103,104,128</sup> Furthermore, numerous retrospective studies<sup>23,24,26,29,31–33,67,73,74,77–79,129,130</sup> and some post hoc analyses of RCTs<sup>47–49,71,76,94,131,132</sup> have shown that higher biologic drug concentrations are associated with favorable short-term and long-term therapeutic outcomes in IBD ([Supplementary Table 1](#), [Tables 1](#) and [2](#)). There do appear to be certain clinical scenarios that proactive TDM of anti-TNF therapy can efficiently guide therapeutic decisions, such as treatment de-escalation,<sup>133</sup> the application of optimized monotherapy instead of combo therapy with immunomodulator,<sup>82</sup> restarting therapy after a long drug holiday,<sup>27</sup> and treatment cessation on deep remission.<sup>50,51</sup>

Nevertheless, before TDM can be widely applied in clinical practice, there are several obstacles to their regular use including when to use TDM, how to accurately interpret and apply the results of such testing, and in defining the optimal drug concentration thresholds and ranges to target.<sup>134</sup> We believe these consensus statements help address these issues and hope they will aid physicians in better understanding and using TDM.

Major limitations of the evidence and consequently these consensus statements relate to the lack of large prospective studies and RCTs on TDM of biologic therapy applied on different IBD phenotypes and sparse data on induction therapy and on biologic agents other than infliximab and adalimumab. Moreover, it is unclear whether trough concentrations are the best predictor of initial response to biologics, compared with peak drug concentrations or total drug exposure. However, in the absence of RCTs, consensus guidelines synthesizing the literature and extrapolating from available data serve to support clinicians in clinical decision-making.

Further RCTs to establish the utility of proactive TDM, particularly during the induction phase, should be performed. Additional future directions should include the

development of accurate, easily accessible, and affordable rapid assays and dashboards to allow fast dosing adaptation and incorporation of predictive PK models based on patient and disease characteristics.<sup>66,135</sup>

In conclusion, there is a growing body of evidence that demonstrates the clinical utility of TDM of biologic therapy in IBD. This is a big step toward personalized medicine and optimizing the care of patients with IBD. Although more prospective data are needed especially for proactive TDM, induction therapy, and non-anti-TNF biologics, these consensus statements provide a practical guide to apply TDM for optimizing biologic therapy in patients with IBD.

## Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at [www.cghjournal.org](http://www.cghjournal.org), and at <https://doi.org/10.1016/j.cgh.2019.03.037>.

## References

- Miligkos M, Papamichael K, Vande Casteele N, et al. Efficacy and safety profile of anti-tumor necrosis factor- $\alpha$  versus anti-integrin agents for the treatment of Crohn's disease: a network meta-analysis of indirect comparisons. *Clin Ther* 2016; 38:1342–1358.
- Katsanos KH, Papamichael K, Feuerstein JD, et al. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. *Clin Immunol* 2018 Mar 12 [Epub ahead of print].
- Ben-Horin S, Chowers Y. Loss of response to anti-TNF treatments in Crohn's disease. *Aliment Pharmacol Ther* 2011;33:987–995.
- Papamichael K, Vande Casteele N, Ferrante M, et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. *Inflamm Bowel Dis* 2017;23:1510–1515.
- Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. *Inflamm Bowel Dis* 2015;21:182–197.
- Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. *Frontline Gastroenterol* 2016; 7:289–300.
- Barclay ML, Karim S, Helms ETJ, et al. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. *Intern Med J* 2019;49:513–518.
- Roblin X, Rinaudo M, Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. *Am J Gastroenterol* 2014;109:1250–1256.
- Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2014;12:80–84.
- Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and anti-drug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. *Clin Gastroenterol Hepatol* 2015;13:522–530.
- Aguas Peris M, Bosó V, Navarro B, et al. Serum adalimumab levels predict successful remission and safe deintensification in inflammatory bowel disease patients in clinical practice. *Inflamm Bowel Dis* 2017;23:1454–1460.
- Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis* 2016;22:409–415.
- Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF- $\alpha$  therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2016;14:550–557.
- Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. *Inflamm Bowel Dis* 2014; 20:1714–1721.
- Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. *Aliment Pharmacol Ther* 2014; 40:620–628.
- Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. *J Gastroenterol* 2014;49:100–109.
- Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. *J Gastroenterol* 2014;49:674–682.
- Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. *J Crohns Colitis* 2016; 10:510–515.
- Morita Y, Imaeda H, Nishida A, et al. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. *J Gastroenterol Hepatol* 2016; 31:1831–1836.
- Morita Y, Bamba S, Takahashi K, et al. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor- $\alpha$  antibodies in ulcerative colitis. *Scand J Gastroenterol* 2016; 51:934–941.
- Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. *Aliment Pharmacol Ther* 2017;46:873–882.
- Juncadella A, Papamichael K, Vaughn B, et al. Maintenance adalimumab concentrations are associated with biochemical, endoscopic and histologic remission in inflammatory bowel disease. *Dig Dis Sci* 2018;63:3067–3073.
- Ungar B, Engel T, Yablecovitch D, et al. Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the Poetic Study. *Am J Gastroenterol* 2018;113:890–898.
- Ungar B, Glidai Y, Yavzori M, et al. Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases. *J Pediatr Gastroenterol Nutr* 2018;67:507–512.
- Van Hoeve K, Dreesen E, Hoffman I, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. *J Crohns Colitis* 2018;12:1316–1325.
- Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of

- adalimumab in ulcerative colitis. *Aliment Pharmacol Ther* 2014; 40:1324–1332.
27. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of re-initiation of infliximab therapy. *Clin Gastroenterol Hepatol* 2014; 12:1474–1481.
  28. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003;348:601–608.
  29. Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. *Gut* 2016;65:1126–1131.
  30. Papamichael K, Baert F, Tops S, et al. Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. *J Crohns Colitis* 2017; 11:53–59.
  31. Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. *Aliment Pharmacol Ther* 2018; 48:731–739.
  32. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. *Gut* 2014;63:1258–1264.
  33. Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of anti-drug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. *Clin Gastroenterol Hepatol* 2016;14:251–258.
  34. Brandse JF, Mould D, Smeekes O, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. *Inflamm Bowel Dis* 2017;23:650–660.
  35. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2015;13:514–521.
  36. El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn's disease in children. *Inflamm Bowel Dis* 2019;25:150–155.
  37. Kelly OB, Donnell SO, Stempak JM, et al. Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease. *Inflamm Bowel Dis* 2017;23:1202–1209.
  38. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. *Clin Gastroenterol Hepatol* 2017; 15:1580–1588.
  39. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. *Inflamm Bowel Dis* 2014;20:1996–2003.
  40. Roblin X, Boschetti G, Duru G, et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. *Inflamm Bowel Dis* 2017; 23:2048–2053.
  41. Marits P, Landucci L, Sundin U, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. *J Crohns Colitis* 2014; 8:881–889.
  42. Yarur A, Kubiliun M, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. *Clin Gastroenterol Hepatol* 2015;13:1118–1124.
  43. Huang VW, Prosser C, Kroeker KI, et al. Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy. *Inflamm Bowel Dis* 2015;21:1359–1367.
  44. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. *Scand J Gastroenterol* 2011;46:310–318.
  45. Papamichael K, Rakowsky S, Rivera C, et al. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. *Aliment Pharmacol Ther* 2018;47:478–484.
  46. Magro F, Afonso J, Lopes S, et al. Clinical performance of an infliximab rapid quantification assay. *Therap Adv Gastroenterol* 2017;10:651–660.
  47. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. *Gastroenterology* 2014; 147:1296–1307.
  48. Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. *J Crohns Colitis* 2017;11:35–46.
  49. Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease. *Gastroenterology* 2018;154:1660–1671.
  50. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. *Gastroenterology* 2012;142:63–70.
  51. Papamichael K, Vande Casteele N, Gils A, et al. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. *Clin Gastroenterol Hepatol* 2015;13:1103–1110.
  52. Kang B, Choi SY, Choi YO, et al. Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn's disease patients treated with combined immunosuppressive therapy. *J Crohns Colitis* 2018; 12:644–652.
  53. Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. *Aliment Pharmacol Ther* 2017;45:933–940.
  54. Fay S, Ungar B, Paul S, et al. The association between drug levels and endoscopic recurrence in postoperative patients with Crohn's disease treated with tumor necrosis factor inhibitors. *Inflamm Bowel Dis* 2017;23:1924–1929.
  55. Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations

- with disease activity and influencing factors. *Aliment Pharmacol Ther* 2017;46:150–161.
56. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. *Aliment Pharmacol Ther* 2014;39:1126–1135.
  57. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology* 2009;137:1628–1640.
  58. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. *Aliment Pharmacol Ther* 2008;28:1122–1126.
  59. Papamichael K, Rakowsky S, Rivera C, et al. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic and histologic remission in Crohn's disease. *Inflamm Bowel Dis* 2018;24:2266–2271.
  60. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. *Gut* 2015;64:1539–1545.
  61. Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. *Clin Gastroenterol Hepatol* 2015;13:539–547.
  62. Bodini G, Giannini EG, Savarino V, et al. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission inpatients with inflammatory bowel disease. *Dig Liver Dis* 2018;50:452–456.
  63. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. *Am J Gastroenterol* 2013;108:962–971.
  64. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2014;20:1708–1713.
  65. Farkas K, Rutka M, Golovics PA, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. *J Crohns Colitis* 2016;10:1273–1278.
  66. Van Stappen T, Bollen L, Vande Casteele N, et al. Rapid test for infliximab drug concentration allows immediate dose adaptation. *Clin Transl Gastroenterol* 2016;7:e206.
  67. Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. *Clin Gastroenterol Hepatol* 2016;14:543–549.
  68. Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. *Clin Gastroenterol Hepatol* 2015;13:531–538.
  69. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. *J Crohns Colitis* 2013;7:736–743.
  70. Hibi T, Sakuraba A, Watanabe M, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. *J Gastroenterol* 2014;49:254–262.
  71. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. *Gut* 2014;63:1721–1727.
  72. Stein R, Lee D, Leonard MB, et al. Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn's disease. *Inflamm Bowel Dis* 2016;22:1370–1377.
  73. Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. *Aliment Pharmacol Ther* 2018;47:212–218.
  74. Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn's disease. *J Crohns Colitis* 2017;11:549–555.
  75. Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. *Aliment Pharmacol Ther* 2018;47:346–355.
  76. Dreesen E, D'Haens G, Baert F, et al. Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX. *J Crohns Colitis* 2018;12(Suppl 1):S063–S064.
  77. Gonczi L, Vegh Z, Golovics PA, et al. Prediction of short- and medium-term efficacy of biosimilar infliximab therapy: do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role? *J Crohns Colitis* 2017;11:697–705.
  78. Kobayashi T, Suzuki Y, Motoya S, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis: results from a multicenter prospective randomized controlled trial and its post hoc analysis. *J Gastroenterol* 2016;51:241–251.
  79. Papamichael K, Rivals-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary nonresponse to infliximab. *J Crohns Colitis* 2016;10:1015–1023.
  80. Steenholdt C, Frederiksen MT, Bendtzen K, et al. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. *J Clin Gastroenterol* 2016;50:483–489.
  81. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2013;19:2568–2576.
  82. Lega S, Phan BL, Rosenthal CJ, et al. Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD. *Inflamm Bowel Dis* 2019;25:134–141.
  83. Guiotto C, Daperno M, Frigerio F, et al. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. *Dig Liver Dis* 2016;48:138–143.
  84. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')<sub>2</sub>, but measuring antibodies to the intact infliximab molecule is more clinically useful. *Gut* 2011;60:41–48.
  85. Buurman DJ, Maurer JM, Keizer RJ, et al. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. *Aliment Pharmacol Ther* 2015;42:529–539.
  86. Papamichael K, Vajravelu RK, Osterman MT, et al. Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease. *Dig Dis Sci* 2018;63:761–767.
  87. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical

- efficacy of infliximab in Crohn's disease. *Am J Gastroenterol* 2008;103:944–948.
88. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology* 2003;124:917–924.
  89. Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2017;15:1427–1434.
  90. Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2018;16:1937–1946.
  91. Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. *Aliment Pharmacol Ther* 2018;47:906–912.
  92. Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. *Clin Gastroenterol Hepatol* 2017;15:1750–1757.
  93. Detrez I, Dreesen E, Van Stappen T, et al. Variability in golimumab exposure: a 'real-life' observational study in active ulcerative colitis. *J Crohns Colitis* 2016;10:575–581.
  94. Vande Casteele N, Feagan BG, Vermeire S, et al. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. *Aliment Pharmacol Ther* 2018;47:229–237.
  95. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2014;12:423–431.
  96. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. *Gastroenterology* 2017;153:827–834.
  97. Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. *Aliment Pharmacol Ther* 2017;46:1037–1053.
  98. Restellini S, Chao CY, Lakatos PL, et al. Therapeutic drug monitoring guides the management of crohn's patients with secondary loss of response to adalimumab. *Inflamm Bowel Dis* 2018;24:1531–1538.
  99. Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut* 2014;63:919–927.
  100. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. *Dig Dis Sci* 2015;60:2762–2770.
  101. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. *Clin Gastroenterol Hepatol* 2013;11:654–666.
  102. Guidi L, Pugliese D, Panici Tonucci T, et al. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. *J Crohns Colitis* 2018 May 31 [Epub ahead of print].
  103. Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. *J Crohns Colitis* 2018;12:804–810.
  104. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology* 2015;148:1320–1329.
  105. Amiot A, Hulin A, Belhassan M, et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. *Clin Res Hepatol Gastroenterol* 2016;40:90–98.
  106. Selinger CP, Lenti MV, Clark T, et al. Infliximab therapeutic drug monitoring changes clinical decisions in a virtual biologics clinic for inflammatory bowel disease. *Inflamm Bowel Dis* 2017;23:2083–2088.
  107. Attar A, Duru G, Roblin X, et al. Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: a discrete event model study. *Dig Liver Dis* 2019;51:112–119.
  108. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. *Am J Gastroenterol* 2015;110:1324–1338.
  109. Billiet T, Cleynen I, Ballet V, et al. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. *Aliment Pharmacol Ther* 2016;44:673–683.
  110. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. *Am J Gastroenterol* 2010;105:1133–1139.
  111. Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. *J Crohns Colitis* 2015;9:238–245.
  112. Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post-hoc analysis. *Clin Gastroenterol Hepatol* 2018 Sep 26 [Epub ahead of print].
  113. Al-Bawardy B, Ramos GP, Willich MAV, et al. Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. *Inflamm Bowel Dis* 2019;25:580–586.
  114. Jentzer A, Emmanuelle Berger A, Labetoulle R, et al. Short communication: evaluation of infliximab and anti-infliximab LISA-TRACKER immunoassays for the therapeutic drug monitoring of SB2 infliximab biosimilar. *Ther Drug Monit* 2018 Sep 21 [Epub ahead of print].
  115. Afonso J, de Sousa HT, Rosa I, et al. Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. *Therap Adv Gastroenterol* 2017;10:661–671.
  116. Schulze K, Koppka N, Lutter F, et al. CT-P13 (Inflixtra, Remsima) monitoring in patients with inflammatory bowel disease. *Biologicals* 2016;44:463–466.

117. Gils A, Van Stappen T, Dreesen E. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. *Inflamm Bowel Dis* 2016;22:969–975.
118. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. *Am J Gastroenterol* 2014;109:1055–1064.
119. Van Stappen T, Vande Castele N, Van Assche G, et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. *Gut* 2018; 67:818–826.
120. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. *Inflamm Bowel Dis* 2012;18:1628–1633.
121. Vande Castele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. *Aliment Pharmacol Ther* 2012;36:765–771.
122. Vande Castele N. Assays for measurement of TNF antagonists in practice. *Frontline Gastroenterol* 2017;8:236–242.
123. Marini JC, Senddecki J, Cornillie F, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade. *AAPS J* 2017; 19:161–171.
124. Singh S, George J, Boland BS, et al. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. *J Crohns Colitis* 2018;12:635–643.
125. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology* 2014;147:618–627.
126. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF Therapy. *Am J Gastroenterol* 2017;112:673–676.
127. Papamichael K, Osterman MT, Siegel CA, et al. Using proactive therapeutic drug monitoring of anti-tumor necrosis factor therapy in inflammatory bowel disease: from an old concept to a future standard of care? *Gastroenterology* 2018;154:1201–1202.
128. Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. *J Crohns Colitis* 2019 Jan 21 [Epub ahead of print].
129. Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. *J Crohns Colitis* 2019 Jan 30 [Epub ahead of print].
130. Pouillon L, Rousseau H, Busby-Venner, et al. Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis. *J Crohns Colitis* 2019 Jan 29 [Epub ahead of print].
131. Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. *Aliment Pharmacol Ther* 2019; 49:408–418.
132. Vande Castele N, Jeyarajah J, Jairath V, et al. Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis. *Clin Gastroenterol Hepatol* 2018 Oct 26 [Epub ahead of print].
133. Lucidarme C, Petitcollin A, Brochard C, et al. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. *Aliment Pharmacol Ther* 2019; 49:147–154.
134. Grossberg LB, Papamichael K, Feuerstein JD, et al. A survey study of gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. *Inflamm Bowel Dis* 2017;24:191–197.
135. Mould DR, Upton RN, Wojciechowski J, et al. Dashboards for therapeutic monoclonal antibodies: learning and confirming. *AAPS J* 2018;20:76.

---

#### Reprint requests

Address requests for reprints to: Adam S. Cheifetz, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Gastroenterology, Department of Medicine, 330 Brookline Avenue, East Campus, Rabb 425, Boston, Massachusetts 02215. e-mail: [acheifet@bidmc.harvard.edu](mailto:acheifet@bidmc.harvard.edu); fax: (617) 667-5826.

#### Conflicts of interest

These authors disclose the following: G.Y.M. has received research funding from Pfizer, Prometheus, and Shire and is a consultant for AbbVie, Genentech, Luitpold Pharmaceuticals, Janssen, UCB, Celgene, Takeda, Genentech, and Pfizer. P.M.I. is on the Advisory Board and Speaker's Bureau for AbbVie, MSD, and Takeda. L.E.R. has served on the Advisory Board for Ferring Pharmaceuticals with all honoraria paid to Mayo Clinic and is a consultant for Alivio Therapeutics. L.B. has served as a consultant for Pfizer, Janssen, Shire, and Takeda and served as speaker for Janssen, Shire, and Takeda. J.J. has served as a speaker for Janssen, Merck, Schering-Plough, Abbot, and AbbVie and has participated in advisory boards for Janssen, Abbott, and Takeda. G.G.K. has served as a speaker for Pfizer, Janssen, Merck, Schering-Plough, and AbbVie; has participated in advisory board meetings for Janssen and AbbVie; and has received research support from GlaxoSmithKline, Merck, and AbbVie. M.P.S. has received educational grants and research support from Ferring Pharmaceuticals and Orphan Pharmaceuticals; speaker's fees from Janssen, AbbVie, Ferring, Takeda, Pfizer, and Shire; and is on the Advisory Boards of Janssen, Takeda, Pfizer, Celgene, AbbVie, and MSD. B.B. is on the Advisory Board of AbbVie, Janssen, Takeda, Shire, Genentech, Ferring, and Warner Chilcott; the Speaker's Bureau of AbbVie, Janssen, Takeda, and Forrest Laboratory; is a consultant for Celltrion and Pendopharm; and has received research support from AbbVie, Amgen, BMS, Genentech, Janssen, BI, and GlaxoSmithKline. A.S.C. has served on advisory boards for AbbVie, Janssen, Takeda, Pfizer, Arena, Samsung, and Bacainn and has received research support from Miraca. S.M.D. has served on Speaker's Bureau and as a consultant for Takeda, Janssen, and AbbVie. N.V.C. has received consultancy fees from Pfizer, Progenity, and Takeda and has received research support from Takeda. C.A.S. has received research funding from AbbVie, Janssen, Takeda, and UCB; delivered CME lectures for AbbVie, Janssen, Merck, and Takeda; and served as an advisor/consultant for AbbVie, Amgen, Janssen, Lilly, Pfizer, Takeda, and Theradiag. The remaining authors disclose no conflicts.

#### Funding

Supported by unrestricted educational grants from Takeda, Pfizer, and AbbVie. Funders had no role in the study design, analysis or interpretation of data, review of the manuscript, or decision to publish. Funders were not present at the moderated panel discussions. K.P. is supported by Ruth L. Kirschstein NRSA Institutional Research Training Grant 5T32DK007760-18. The content of this project is solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH).

**Supplementary Table 1.** Serum Infliximab Concentration Thresholds Associated With Therapeutic Outcomes in Inflammatory Bowel Disease

IBD type	Time point	Threshold ( $\mu\text{g/mL}$ )	Therapeutic outcome	TDM assay	Assay type	Reference
<b>Induction</b>						
CD	w2	>16.9 <sup>a</sup>	Clinical response (w14)	ELISA	Theradiag	77
CD	w2	>9.2	Clinical remission (w14)	ELISA	AHLC	24
CD	w2	>23.1	Endoscopic remission (w12)	ELISA	Leuven assay	76
CD	w2	>20.4 <sup>a</sup>	Clinical remission (w14)	ELISA	Theradiag	77
CD	w2	>9.2	Fistula response (w14)	ELISA	AHLC	74
CD	w2	>9.2	Fistula response (w30)	ELISA	AHLC	74
UC	w2	>21.3	Clinical remission (w14)	ELISA	Mitsubishi Tanabe Pharma Corp	78
UC	w2	$\geq$ 28.3	Mucosal healing (w10–14)	ELISA	Leuven drug-tolerant assay	67
UC	w2	<16.5	Colectomy	ELISA	Leuven assay	79
UC	w2	>11.5 <sup>a</sup>	Clinical response (w14)	ELISA	Theradiag	77
UC	w2	>11.5 <sup>a</sup>	Clinical response (w30)	ELISA	Theradiag	77
UC	w2	>15.3 <sup>a</sup>	Clinical remission (w14)	ELISA	Theradiag	77
UC	w2	>14.5 <sup>a</sup>	Clinical remission (w30)	ELISA	Theradiag	77
UC	w2	$\geq$ 18.6	MES <2 (w8)	ELISA	Janssen Biotech Inc	132
CD/UC	w2	<6.8	PNR (w14)	ELISA	AHLC	73
CD	w6	>10	Endoscopic remission (w12)	ELISA	Leuven assay	76
CD	w6	>7.2	Fistula response (w14)	ELISA	AHLC	74
CD	w6	>8.6	Fistula response (w30)	ELISA	AHLC	74
CD	w6	>2.2	Drug retention beyond 1 year of treatment	ELISA	AHLC	24
UC	w6	$\geq$ 15	Mucosal healing (w10–14)	ELISA	Leuven drug-tolerant assay	67
UC	w6	>6.6	Endoscopic response (w8)	ELISA	Sanquin Diagnostics	33
UC	w6	>22	Clinical response (w8)	ELISA	Janssen Biotech Inc	47
CD/UC	w6	<3.5	PNR (w14)	ELISA	AHLC	73
CD/UC	w6	<13	ATI formation	HMSA	Prometheus	63
<b>Post-induction</b>						
UC	w8	>41.1	Clinical response (w8)	ELISA	Janssen Biotech Inc	47
CD	w10	$\geq$ 9.1	Drug retention (w52)	HMSA	Prometheus	72
CD	w14	>12.7	Fistula response (w24)	ELISA	Dynacare Laboratories	36
CD	w14	>3.5	Clinical response (w54)	ELISA	Janssen Biotech Inc	71
CD	w14	<1	SLR (w54)	ELISA	Janssen Biotech Inc	70
CD	w14/22	>3	Sustained clinical response	ELISA	Matriks Biotek	69
UC	w14	>2.5	Colectomy-free survival	ELISA	In-house Leuven	68
UC	w14	$\geq$ 2.1	Mucosal healing (w10–14)	ELISA	Leuven drug-tolerant assay	67
UC	w14	$\geq$ 2.1	Mucosal healing (w10–14)	LFA	R-Biopharm AG	66
UC	w14	>5.1	Clinical response (w30)	ELISA	Janssen Biotech Inc	47
UC	w14	>3.2 <sup>a</sup>	Mucosal healing	ELISA	Theradiag/Matriks Biotek	65
UC	w14	>3.2 <sup>a</sup>	Steroid-free remission	ELISA	Theradiag/Matriks Biotek	65
CD/UC	w14	>5.5	Clinical remission (w54)	HMSA	Prometheus	64
CD/UC	w14	<2.2	Treatment failure	HMSA	Prometheus	63
CD/UC	w14	<6.2	Loss of response (w48)	HMSA	Prometheus	62
<b>Maintenance</b>						
CD	w30	$\geq$ 3	Mucosal healing (w26)	ELISA	Janssen Biotech Inc	61

Supplementary Table 1. Continued

IBD type	Time point	Threshold ( $\mu\text{g/mL}$ )	Therapeutic outcome	TDM assay	Assay type	Reference
CD		>2.8	Normal CRP ( $\leq 5$ mg/L)	HMSA	Prometheus	60
CD		$\geq 2.2$	Normal CRP ( $\leq 5$ mg/L)	HMSA/ELISA	Prometheus	59
CD		$\geq 9.7$	Endoscopic remission	HMSA/ELISA	Prometheus	59
CD		$\geq 9.8$	Histologic remission	HMSA/ELISA	Prometheus	59
CD		>0.6	Normal CRP ( $\leq 0.3$ mg/dL)	ELISA	MP Biomedicals	17
CD		>1.1	Normal FC ( $< 300$ $\mu\text{g/g}$ )	ELISA	MP Biomedicals	17
CD		>4	Mucosal healing	ELISA	MP Biomedicals	17
CD		<3	Mean CDAI increase $\geq 70$	HMSA	Prometheus	56
CD		>2.7	Mucosal healing	ELISA	In-house	20
CD		>1.5	Clinical remission	ELISA	Theradiag	55
CD		>3.4	Normal CRP ( $\leq 5$ mg/L)	ELISA	Theradiag	55
CD		>5.7	Normal FC ( $< 59$ $\mu\text{g/g}$ )	ELISA	Theradiag	55
CD		<1.8	Significant endoscopic recurrence	ELISA	AHLC/Theradiag	54
CD		>10.1	Fistula healing	HMSA	Prometheus	53
CD		>10.1	Mucosal healing	HMSA	Prometheus	53
CD		$\geq 2.5$	Relapse after anti-TNF withdrawal	ELISA	Matriks Biotek	52
CD		$\geq 6$	Relapse after anti-TNF withdrawal	ELISA	Leuven assay	51
CD		$\geq 2$	Relapse after anti-TNF withdrawal	ELISA	In-house <sup>P</sup>	50
UC	w30	>2.4	Clinical response (w54)	ELISA	Janssen Biotech Inc	47
UC		>3	Normal FC ( $< 250$ mg/g)	ELISA	LFA Bühlmann/Sanquin	46
UC		>3	Mucosal healing	ELISA	LFA Bühlmann/Sanquin	46
UC		$\geq 7.5$	Endoscopic healing	HMSA/ELISA	Prometheus	45
UC		$\geq 10.5$	Histologic healing	HMSA/ELISA	Prometheus	45
CD/UC		<0.5	SLR	RIA	Biomonitor A/S	44
CD/UC		>6.8	Normal CRP ( $\leq 5$ mg/L)	ELISA	AHLC	13
CD/UC		>5	Mucosal healing	ELISA	AHLC	13
CD/UC		>7.3	Normal FC ( $< 250$ mg/g)	ELISA	Immunodiagnostik	43
CD/UC		>8.3	Mucosal healing	HMSA	Prometheus	42
CD/UC		>4.1	Clinical remission	ELISA	In-house	41
CD/UC		>2.1	Clinical remission	ELISA	Theradiag	40
CD/UC		>2.9	Clinical remission and normal CRP ( $\leq 5$ mg/L)	ELISA	Theradiag	40
CD/UC		>3.9	Clinical remission and normal FC ( $< 250$ mg/g)	ELISA	Theradiag	40
CD/UC		>4.9	Clinical remission, normal CRP ( $\leq 5$ mg/L) and normal FC ( $< 50$ mg/g)	ELISA	Theradiag	40
CD/UC		$\geq 5$	Drug retention	ELISA/HMSA	Prometheus	39
CD/UC		<3.5	Treatment failure	HMSA	Prometheus	38
CD/UC		<4.6	IBD-related hospitalization	HMSA	Prometheus	38
CD/UC		<1.8	Detectable ATI	HMSA	Prometheus	38
CD/UC		<6.3	Serious infusion reaction	HMSA	Prometheus	38
CD/UC		>3.8	When SLR, better long-term outcome when change to a biological with a different mechanism of action	ELISA	AHLC	10



CD/UC	≥4.5	compared with anti-TNF dosage increase or a switch within class	HMSA	Prometheus	37
CD/UC	>5	Post-adjustment endoscopic remission	ELISA	Leuven assay	35
		Lower risk for an IBD-related surgery and dose escalation or drug cessation for SLR after withdrawal of the immunomodulator			
CD/UC	<3	ATI formation	ELISA	Sanquin Diagnostics	34
CD/UC	>5.1	Clinical remission	ELISA	New Zealand assay	7
CD/UC	>5.4	Endoscopic remission	ELISA	Leuven	25

AHLC, antihuman lambda chain antibody; ATI, antibodies to infliximab; CD, Crohn's disease; CDAI, Crohn's disease activity index; CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; FC, fecal calprotectin; HMSA, homogeneous mobility shift assay; IBD, inflammatory bowel disease; LFA, lateral flow-based assay; MES, Mayo endoscopic score; PNR, primary non-response; RIA, radioimmunoassay; SLR, secondary loss of response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor; UC, ulcerative colitis; w, week.

<sup>a</sup>Infliximab biosimilar CT-P13.

<sup>b</sup>Université François-Rabelais, Immuno-Pharmaco-Genetics of Therapeutic Antibodies, Tours, France.